<p>The HCI-PDX Trial Center for Breast Cancer Therapy study is a collection of patient-tumor samples that are serially established as patient-derived tumor xenografts (human tumor in mouse) and matching organoids. For this study, we describe valuable methods and resources to generate organoids and use them as cost-effective models for precision drug screens. This study leveraged whole-exome sequencing, RNAseq, and SNP-array data to illustrate how the heterogeneity of tumors is preserved in xenograft and organoid models. Sequencing files are provided for whole-exome and RNAseq data. Processed copy number variant calls from the SNP arrays are also available. A full description of the study can be found in the article entitled, "A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology," written by Guillen et al., 2022 in Nature Cancer (PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35221336/">35221336</a>).</p>

HCI-PDX Trial Center for Breast Cancer Therapy

Breast Neoplasms study with CNV Genotypes, RNA-Seq + 3 more data on dbGaP (37 participants)

HCI-PDX Trial Center for Breast Cancer Therapy

Description

Applying For Access

Summary